NCT03296345View on ClinicalTrials.gov

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Sickle Cell DiseaseVaso-Occlusive Crisis
Interventions
DRUG

Ketamine

The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).

Trial Locations (1)

94609

UCSF Benioff Children's Hospital and Research Center Oakland, Oakland

All Listed Sponsors
lead

UCSF Benioff Children's Hospital Oakland

OTHER

NCT03296345 - Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis | Biotech Hunter | Biotech Hunter